| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BREAST.2016.07.015 |
| P698 | PubMed publication ID | 27481651 |
| P50 | author | Sherene Loi | Q42315566 |
| P2093 | author name string | Peter Savas | |
| Roberto Salgado | |||
| Stephen Luen | |||
| Balaji Virassamy | |||
| P2860 | cites work | Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer | Q28268284 |
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| P304 | page(s) | 241-250 | |
| P577 | publication date | 2016-07-29 | |
| P1433 | published in | The Breast | Q7719928 |
| P1476 | title | The genomic landscape of breast cancer and its interaction with host immunity | |
| P478 | volume | 29 |
| Q92477581 | A Spontaneous Aggressive ERα+ Mammary Tumor Model Is Driven by Kras Activation |
| Q41701208 | Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer |
| Q48113563 | Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. |
| Q57937919 | Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival |
| Q55360303 | Breast Cancer Immunotherapy: An Update. |
| Q38628198 | Breast Cancer Immunotherapy: Facts and Hopes |
| Q89918629 | Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1 |
| Q57110111 | Checkpoint blockade in the treatment of breast cancer: current status and future directions |
| Q90356734 | Clinical implications of APOBEC3A and 3B expression in patients with breast cancer |
| Q48311135 | Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer |
| Q33918347 | Common shared genetic variation behind decreased risk of breast cancer in celiac disease |
| Q98892917 | Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis |
| Q92513062 | Genetic Alterations in Benign Breast Biopsies of Subsequent Breast Cancer Patients |
| Q55508841 | Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. |
| Q92416131 | Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review |
| Q90683679 | Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast |
| Q99408679 | Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers |
| Q42357389 | Inflammation, phagocytosis and cancer: another step in the CD47 act. |
| Q99565898 | Innovative approaches to immunotherapy in breast cancer |
| Q47156322 | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. |
| Q57107866 | Is there a role for immunotherapy in HER2-positive breast cancer? |
| Q90437273 | Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer |
| Q58768185 | Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer |
| Q92615724 | Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity |
| Q47261659 | Protein biomarkers for subtyping breast cancer and implications for future research. |
| Q47706658 | Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. |
| Q55182988 | Targeting immune checkpoints in breast cancer: an update of early results. |
| Q47564468 | Triple negative breast cancer - prognostic role of immune-related factors: a systematic review. |
| Q58567735 | Tumor mutational burden is a determinant of immune-mediated survival in breast cancer |
| Q49789105 | Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes? |
Search more.